The $15M total investment round that Remepy, a hybrid medication development company in New York, closed with the addition of $10M to its previous funding round.
Investors
- TechAviv
- Fresh.fund
- Samsung Next
- StageNext Fund
- 97212 Ventures
- the round was headed by NFX
- Vine Ventures
- PsyMed Ventures
- Supernode Ventures
- Firstime Ventures
Remepy is at the forefront of the development of hybrid pharmaceuticals, which mix traditional medications with tailored digital therapies to improve the efficacy of pharmacological treatments. The company is led by Dr. Michal Tsur and Or Shoval.
Digital molecules are medicinal agents that act on the brain’s mechanisms of action, or MOAs, to produce physiological effects. It has been demonstrated that these physiological alterations increase the efficacy of conventional medications.
The business has already demonstrated the effectiveness of its medicines in human trials utilizing blood and saliva samples, thorough brain imaging, and MCI, with encouraging outcomes for cancer, Parkinson’s disease, and MCI.
Remepy focuses on autoimmune disorders, cancer, degenerative eye illnesses, and neurodegenerative diseases.
About Remepy
Remepy is at the forefront of the development of hybrid pharmaceuticals, which mix traditional medications with individualized digital therapies to improve the efficacy of prescription medications. Remepy has demonstrated the efficacy of its medicines in human research through the use of blood and saliva samples, comprehensive brain imaging, and promising outcomes for Parkinson’s disease, cancer, and motor cortex injury. Their strategy opens up a whole new market and data universe by providing an effective way to produce new patented pharmaceutical assets. Renowned medical professionals, technicians, and scientists make up the Remepy team.
